Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $6.94 Analyst target: $13.65 Upside: 96.69%
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.